ANCHOR (Aneurysm Treatment Using the Heli-FX Aortic Securement System Global Registry)

Study Arms:

Abdominal Arm: Subjects with abdominal aortic aneurysms that do not require placement of
EndoAnchors™ above the level of the renal arteries will be considered part of the abdominal
arm. If a renal artery or any visceral artery requires (a) chimney procedure(s), the subject
will be considered part of the Advanced Disease arm.

Thoracic Arm: Subjects with thoracic aortic aneurysms that do not require placement of any
EndoAnchors proximal to the left common carotid artery (LCCA) or distal to the celiac artery.
Thoracic procedures which require arch vessel transposition(s) or bypass procedures to the
LCCA or brachiocephalic artery, chimney procedures into any arch or visceral artery(s), or
hybrid open-endovascular repairs to the aorta will be considered part of the Advanced Disease
Arm.

Advanced Disease Arm: To collect data on consecutively treated patients, the Advanced Disease
Arm will be comprised of subjects that required placement of EndoAnchors proximal to the LCCA
or in the visceral segment of the aorta distal to the celiac artery and proximal to the renal
arteries. Subjects with thoracic procedures which require arch vessel transposition(s) or
bypass (except to the left subclavian artery) or hybrid open-endovascular procedures as well
as those with abdominal or thoracic procedures that require chimney procedures into any renal
or visceral artery should also be included in the Advanced Disease arm.

Primary Group: Assess the Aptus HeliFX Aortic Securement System placed at the time of initial
endograft implantation, either to prevent endograft migration and Type Ia endoleak, or to
treat Type Ia endoleak evident at the time of implantation.

Revision Group: Assess the Aptus HeliFX™ Aortic Securement System in subjects with previously
implanted commercial endografts, for the prevention of graft migration and the treatment of
Type Ia endoleak.

Inclusion Criteria:

- Subjects with asymptomatic, symptomatic, or ruptured abdominal aortic aneurysms

- Subject ≥ 18 years old

- Subject has provided written informed consent, either before or less than or equal to
30 calendar days after the index procedure

- Subject is willing and able to comply with standard of care follow-up evaluations

- Subject has a previously implanted endograft (Revision Group), or will be undergoing
repair (Primary Group), with one of the following aortic aneurysm endograft devices:

- Cook Zenith or Cook Zenith TX2

- Gore Excluder or TAG

- Medtronic AneuRx

- Medtronic Talent

- Medtronic Endurant or Valiant

- Any additional third party AAA endograft device that is commercially available
and listed as compatible with the Aptus Heli-FX EndoAnchor System in the
Instructions for Use

- Subject's iliac/femoral access is compatible

- a 16 French sheath (abdominal subjects)

- 18 French seath (thoracic subjects)

- Selected 16 or 18 French sheath, as applicable to the device selected for use
(advanced disease subjects)

- Subject has a previously implanted endograft that has migrated or has a Type Ia
endoleak within the aorta (Revision Group) or will undergo implantation of an
endograft that in the opinion of the Investigator will be at increased risk of such
complications (Primary Group)

Exclusion Criteria:

- Subject has known allergy to the EndoAnchor implant material (nickel, chromium,
molybdenum, or cobalt)

- Subject has a life expectancy less than 1 year

- Subject is participating in a clinical study or registry that, in the Investigator's
opinion, may conflict or may have a negative impact on the subject's safety

- Subject was treated with EndoAnchors in the same segment of the aorta that will be
treated in the registry

- Subject has an active or known history of bleeding diathesis

- Subject has a condition that threatens to infect the endograft (active bacteremia, or
infections that carry increased risk of endograft infection)

- Significant thrombus or calcium at the location of planned EndoAnchor implantation
that precludes adequate EndoAnchor penetration of the aortic wall

- Use where, for whatever reason, each EndoAnchor is not anticipated to adequately
penetrate into the aortic wall

- Subject has an aortic dissection that invloves an area to be treated with EndoAnchors

- Subject has Marfan Syndrome, Ehlers Danlos Syndrome, or another collagen vascular
disease

- Subject is pregnant